Q-omics provides the consensus-scored MIR6806 profile across patient tissues and cancer cell-line models. MIR6806 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR6806 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, MIR6806 RNA expression shows 11,107 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, LUAD, and UVM as cancer lineages where MIR6806 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6806 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6806 survival associations across molecular data types. MIR6806 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6806 RNA expression–survival associations across cancer types. High MIR6806 expression shows unfavorable associations in READ, COAD, LGG, STAD and LIHC, but favorable associations in LUAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR6806 RNA expression.
This table summarizes MIR6806 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6806. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6806 shows lower tumor expression in KIRP and higher tumor expression in LUAD. The LUAD box plot shows higher MIR6806 RNA expression in tumor versus normal tissue (log2 FC = +1.290, t-test p = .003).
This table shows molecular features associated with MIR6806 in patient tissues and cancer cell lines. In patient samples, MIR6806 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
